2013 (mNSCLC Metastatic March non-small 2014 outside outside cell lung Jan Dec Erlotinib Tarceva® Aus 8 No 0 None funding Jan 2014 funding cancer and 2006 without 2011 restrictions restrictions pancreatic ECFR cancer mutation), never for pancreatic cancer (first in 2005) for PBS-listed Metastatic mRCC, for mRCC, breast pNET, pNET, outside outside Aus and cancer; Sept Nov 2014 Everolimus Afinitor® 19 Yes 68 None nNET, tuberous funding funding NZ primitive 2009 for SEGA sclerosis restrictions restrictions complex, tumour mBC mBC, SEGA
Erlotinib Tarceva® Aus 8 No Metastatic non-small cell lung cancer and pancreatic cancer 0 None Jan 2006 2013 March 2014 (mNSCLC without ECFR mutation), never for pancreatic cancer outside funding restrictions Dec 2011 Jan 2014 outside funding restrictions Everolimus Afinitor® Aus and NZ 19 Yes Metastatic breast cancer; primitive tumour 68 None (first in 2005) for mRCC, pNET, nNET, mBC, SEGA PBS-listed for mRCC, pNET, tuberous sclerosis complex, mBC outside funding restrictions Sept 2009 Nov 2014 for SEGA outside funding restrictions
1-s2.0-S0168851017303457-mmc1.docx